Craig Berman

Chief Tech/Sci/R&D Officer at SUTRO BIOPHARMA, INC.

Health Technology

Consumer Services

Profile

Craig Berman is currently the Vice President of Clinical Development at Sutro Biopharma, Inc. and QED Therapeutics, Inc. He received his undergraduate degree from Northwestern University in 1987 and his doctorate degree from the University of Colorado Health Sciences Center in 1992.

Craig Berman active positions

Companies	Position	Start
SUTRO BIOPHARMA, INC.	Chief Tech/Sci/R&D Officer	2020-05-20
QED Therapeutics, Inc. QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The private company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017.	Chief Tech/Sci/R&D Officer	2018-09-30

All active positions of Craig Berman

Training of Craig Berman

Northwestern University	Undergraduate Degree
University of Colorado Health Sciences Center	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Craig Berman's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
SUTRO BIOPHARMA, INC.	Health Technology

Private companies	1
QED Therapeutics, Inc. QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The private company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017.	Health Technology